2102101-72-2
Chemical Structure
IPN60090 dihydrochloride
- CAS No.: 2102101-72-2
- Formula:C24H29Cl2F3N8O3
- Molecular Weight:605.44
IUPAC Name: (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide dihydrochloride
InChIKey: MREGZVYRKYDENT-QCUBGVIVSA-N
SMILES: O=C(NC)C1=CN(C[C@H](F)CCC2=NN=C(NC(CC3=NC(C)=CC(OC4CC(F)(F)C4)=C3)=O)C=C2)N=N1.[H]Cl.[H]Cl
Biological Activity: IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
IPN60090 dihydrochloride | 99.68% | IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
IPN60090 dihydrochloride (Standard) | ≥98% | IPN60090 dihydrochloride (Standard) is the analytical standard of IPN60090 dihydrochloride (HY-103671A). This product is intended for research and analytical applications. IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Maria Emilia Di Francesco, et al. Gls1 inhibitors for treating disease. WO2016004404A2.
- [2]. Michael J Soth, et al. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem. 2020 Nov 12;63(21):12957-12977. [Content Brief]
